Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MEETINGS - Medical device forum (France) May 2001:

This article was originally published in Clinica

Executive Summary

Development and marketing of medical devices in Japan, China and Taiwan are on the agenda of the 4th Medical device forum, being held at the Hotel Holiday Inn Garden Court, Illkirch, Strasbourg, France, on May 18-19. Topics for discussion include: the Alsace region: its economic structure and life science; global success by international licensing and marketing; clinical trials for marketing and reimbursement; European regulation for human tissue and cell products; medical device regulation and marketing in Japan; medical device regulation in Taiwan; and government initiatives for the development of the Taiwanese medical device industry. For more information contact Mueller-Lierheim in Germany. Tel: +49 8331 944500. Fax: +49 8331 47478. Email: [email protected]

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT070564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel